Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Onxeo S.A.. (9/30/16). "Press Release: Onxeo Raises €12.5 Million through Capital Increase with US and European Investors [THIS PRESS RELEASE IS NOT FOR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN, OR AUSTRALIA]". Paris & Copenhagen.

Region Region EUR(WEST)+AM(NORTH)
Organisations Organisation Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO)
  Group Onxeo (Group)
  Organisation 2 Financière de la Montagne
Products Product Livatag®
  Product 2 AsiDNA™ (Onxeo / DNA Therapeutics)
Index terms Index term Onxeo–SEVERAL: investment, 201609 capital increase €12.5m with 5.4m new ordinary shares at €2.3/share to US + European institutional investors
  Index term 2 Onxeo–Financière de la Montagne: investment, 201609 capital increase €12.5m incl €1.7m from FdlM keeping its position as largest shareholder w 13.65%
Persons Person Gréciet, Judith (BioAlliance Pharma 201306 CEO + France Biotech 201508 Board Member)
  Person 2 Fellmann, Nicolas (Onxeo 201606 CFO)

Record changed: 2016-10-03


Picture [iito] Plain Stupid Simple 650x80px

More documents for Onxeo (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top